The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Roche
Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.
 
Anne Hansen Ree
Research Funding - Bristol-Mers Squibb (Inst)
 
Jūratė Šaltytė Benth
No Relationships to Disclose
 
Hanne M Hamre
Honoraria - Bayer; Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Incyte
 
Christian Kersten
No Relationships to Disclose
 
Eva Hofsli
No Relationships to Disclose
 
Marianne G Guren
No Relationships to Disclose
 
Halfdan Sorbye
Honoraria - Ipsen; Pierre Fabre; SAM NORDIC
Consulting or Advisory Role - AAA/Endocyte/Novartis; Hutchison MediPharma
 
Christin Johansen
No Relationships to Disclose
 
Anne Negård
No Relationships to Disclose
 
Ying Esbensen
No Relationships to Disclose
 
Tonje Bjørnetrø
No Relationships to Disclose
 
Hedvig V Juul
No Relationships to Disclose
 
Fatemeh Kaveh
No Relationships to Disclose
 
Else Marit Inderberg
No Relationships to Disclose
 
Hilde Loge Nilsen
No Relationships to Disclose
 
Kjersti Flatmark
No Relationships to Disclose
 
Sebastian Meltzer
Research Funding - AstraZeneca (Inst); BMS Norway (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)